Factor Bioscience

Factor Bioscience is a private, pre-clinical stage biotechnology company developing a suite of foundational technologies for next-generation cell engineering. The company leverages its proprietary platforms in mRNA, gene editing (UltraSlice), and delivery to create cell therapies aimed at repairing mutations, conferring disease resistance, and enhancing immune cell function against cancer. With over 150 patents and a collaborative business model, Factor works with strategic partners to advance programs while also spinning out focused ventures like Exacis Biotherapeutics and Novellus Therapeutics.

Integrated platform for cell engineering comprising mRNA technology, the UltraSlice gene-editing system, cell reprogramming, and nucleic acid delivery technologies, protected by over 150 patents.

Factor competes in the crowded gene editing and cell engineering tools sector against large public companies (e.g., CRISPR Therapeutics, Intellia Therapeutics) and numerous well-funded private startups. Its differentiation hinges on the performance of its integrated UltraSlice and delivery platform and its strategy of collaboration and asset spin-outs.